Cassava Sciences Reports Positive Preclinical Results for Simufilam in TSC-Related Epilepsy Model

FILANA THERAPEUTICS, INC.

Simufilam attenuated seizure progression with significant dose-response in Tsc1 conditional knockout mouse model of TSC-related epilepsy.
Study conducted in collaboration with TSC Alliance and TSC Preclinical Consortium, executed by PsychoGenics, Inc.
First clinical proof-of-concept study for simufilam in TSC-related epilepsy is expected to begin in H1 2026.
Results consistent with prior findings published in Science Translational Medicine from Yale School of Medicine.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.